Current status of adjuvant endocrine therapy for hormone responsive breast cancer

T. Ikeda, H. Jinno, S. Masamura, A. Matsui, G. Tajima, T. Hohjoh, H. Tokura, Y. Mitsui, S. Asaga, T. Muto, K. Fujiwara, M. Kitajima

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Three important meetings on adjuvant hormone therapy for breast cancer were held recently: the 5th EBCTCG Meeting, NIH Consensus Meeting, 7th International Conference on Adjuvant Therapy of Primary Breast Cancer. The conclusions of these meetings are: 1. adjuvant hormone therapy should be indicated only for patients with estrogen/progesterone receptor positive cancer, 2. five years of tamoxifen is the standard care at present, 3. ovarian ablation by any means has been proved effective in premenopausal patients and LH-RH agonist should be given at least two years, and 4. aromatase inhibitors should not be used in clinical practice, because several prospective randomized trials are ongoing at present. The patients treated with LH-RH agonist combined with tamoxifen showed better relapse-free survival compared with LH-RH agonist alone in the INT-0101 trial. This was an important trial because combined hormone therapy had not been proven more effective than individual hormone therapy previously. Combined hormone therapy including LH-RH agonist may be considered in premenopausal patients. There is a growing consensus that chemotherapy is effective through the ovarian suppression. In this sense, hormonal therapy should be considered first for hormone responsive patients. On the contrary, standard chemotherapy has shifted from CMF combination to an anthracycline containing regimen. Chemoendocrine therapy may be considered in high risk patients.

Original languageEnglish
Pages (from-to)902-908
Number of pages7
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume28
Issue number7
Publication statusPublished - 2001 Jul

Fingerprint

Hormones
Breast Neoplasms
Gonadotropin-Releasing Hormone
Tamoxifen
Therapeutics
Drug Therapy
Aromatase Inhibitors
Anthracyclines
Progesterone Receptors
Estrogen Receptors
Recurrence
Survival
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Ikeda, T., Jinno, H., Masamura, S., Matsui, A., Tajima, G., Hohjoh, T., ... Kitajima, M. (2001). Current status of adjuvant endocrine therapy for hormone responsive breast cancer. Gan to kagaku ryoho. Cancer & chemotherapy, 28(7), 902-908.

Current status of adjuvant endocrine therapy for hormone responsive breast cancer. / Ikeda, T.; Jinno, H.; Masamura, S.; Matsui, A.; Tajima, G.; Hohjoh, T.; Tokura, H.; Mitsui, Y.; Asaga, S.; Muto, T.; Fujiwara, K.; Kitajima, M.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 28, No. 7, 07.2001, p. 902-908.

Research output: Contribution to journalArticle

Ikeda, T, Jinno, H, Masamura, S, Matsui, A, Tajima, G, Hohjoh, T, Tokura, H, Mitsui, Y, Asaga, S, Muto, T, Fujiwara, K & Kitajima, M 2001, 'Current status of adjuvant endocrine therapy for hormone responsive breast cancer', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 28, no. 7, pp. 902-908.
Ikeda T, Jinno H, Masamura S, Matsui A, Tajima G, Hohjoh T et al. Current status of adjuvant endocrine therapy for hormone responsive breast cancer. Gan to kagaku ryoho. Cancer & chemotherapy. 2001 Jul;28(7):902-908.
Ikeda, T. ; Jinno, H. ; Masamura, S. ; Matsui, A. ; Tajima, G. ; Hohjoh, T. ; Tokura, H. ; Mitsui, Y. ; Asaga, S. ; Muto, T. ; Fujiwara, K. ; Kitajima, M. / Current status of adjuvant endocrine therapy for hormone responsive breast cancer. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2001 ; Vol. 28, No. 7. pp. 902-908.
@article{d4f05715344b4262806a4e8c60ca339a,
title = "Current status of adjuvant endocrine therapy for hormone responsive breast cancer",
abstract = "Three important meetings on adjuvant hormone therapy for breast cancer were held recently: the 5th EBCTCG Meeting, NIH Consensus Meeting, 7th International Conference on Adjuvant Therapy of Primary Breast Cancer. The conclusions of these meetings are: 1. adjuvant hormone therapy should be indicated only for patients with estrogen/progesterone receptor positive cancer, 2. five years of tamoxifen is the standard care at present, 3. ovarian ablation by any means has been proved effective in premenopausal patients and LH-RH agonist should be given at least two years, and 4. aromatase inhibitors should not be used in clinical practice, because several prospective randomized trials are ongoing at present. The patients treated with LH-RH agonist combined with tamoxifen showed better relapse-free survival compared with LH-RH agonist alone in the INT-0101 trial. This was an important trial because combined hormone therapy had not been proven more effective than individual hormone therapy previously. Combined hormone therapy including LH-RH agonist may be considered in premenopausal patients. There is a growing consensus that chemotherapy is effective through the ovarian suppression. In this sense, hormonal therapy should be considered first for hormone responsive patients. On the contrary, standard chemotherapy has shifted from CMF combination to an anthracycline containing regimen. Chemoendocrine therapy may be considered in high risk patients.",
author = "T. Ikeda and H. Jinno and S. Masamura and A. Matsui and G. Tajima and T. Hohjoh and H. Tokura and Y. Mitsui and S. Asaga and T. Muto and K. Fujiwara and M. Kitajima",
year = "2001",
month = "7",
language = "English",
volume = "28",
pages = "902--908",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "7",

}

TY - JOUR

T1 - Current status of adjuvant endocrine therapy for hormone responsive breast cancer

AU - Ikeda, T.

AU - Jinno, H.

AU - Masamura, S.

AU - Matsui, A.

AU - Tajima, G.

AU - Hohjoh, T.

AU - Tokura, H.

AU - Mitsui, Y.

AU - Asaga, S.

AU - Muto, T.

AU - Fujiwara, K.

AU - Kitajima, M.

PY - 2001/7

Y1 - 2001/7

N2 - Three important meetings on adjuvant hormone therapy for breast cancer were held recently: the 5th EBCTCG Meeting, NIH Consensus Meeting, 7th International Conference on Adjuvant Therapy of Primary Breast Cancer. The conclusions of these meetings are: 1. adjuvant hormone therapy should be indicated only for patients with estrogen/progesterone receptor positive cancer, 2. five years of tamoxifen is the standard care at present, 3. ovarian ablation by any means has been proved effective in premenopausal patients and LH-RH agonist should be given at least two years, and 4. aromatase inhibitors should not be used in clinical practice, because several prospective randomized trials are ongoing at present. The patients treated with LH-RH agonist combined with tamoxifen showed better relapse-free survival compared with LH-RH agonist alone in the INT-0101 trial. This was an important trial because combined hormone therapy had not been proven more effective than individual hormone therapy previously. Combined hormone therapy including LH-RH agonist may be considered in premenopausal patients. There is a growing consensus that chemotherapy is effective through the ovarian suppression. In this sense, hormonal therapy should be considered first for hormone responsive patients. On the contrary, standard chemotherapy has shifted from CMF combination to an anthracycline containing regimen. Chemoendocrine therapy may be considered in high risk patients.

AB - Three important meetings on adjuvant hormone therapy for breast cancer were held recently: the 5th EBCTCG Meeting, NIH Consensus Meeting, 7th International Conference on Adjuvant Therapy of Primary Breast Cancer. The conclusions of these meetings are: 1. adjuvant hormone therapy should be indicated only for patients with estrogen/progesterone receptor positive cancer, 2. five years of tamoxifen is the standard care at present, 3. ovarian ablation by any means has been proved effective in premenopausal patients and LH-RH agonist should be given at least two years, and 4. aromatase inhibitors should not be used in clinical practice, because several prospective randomized trials are ongoing at present. The patients treated with LH-RH agonist combined with tamoxifen showed better relapse-free survival compared with LH-RH agonist alone in the INT-0101 trial. This was an important trial because combined hormone therapy had not been proven more effective than individual hormone therapy previously. Combined hormone therapy including LH-RH agonist may be considered in premenopausal patients. There is a growing consensus that chemotherapy is effective through the ovarian suppression. In this sense, hormonal therapy should be considered first for hormone responsive patients. On the contrary, standard chemotherapy has shifted from CMF combination to an anthracycline containing regimen. Chemoendocrine therapy may be considered in high risk patients.

UR - http://www.scopus.com/inward/record.url?scp=0035403487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035403487&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 902

EP - 908

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 7

ER -